Entacapone, a catechol-O-methyltransferase inhibitor for treating Parkinson’s disease: review and current status

By Gottwald M.D.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 4, 1999-04 ,pp. : 453-462

Informa Healthcare

Access to resources Recommend Favorite

BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of l-DOPA to the brain and reduces its O-methylation

By Parada A.   Loureiro A.I.   Vieira-Coelho M.A.   Hainzl D.   Soares-da-Silva P.  

European Journal of Pharmacology, Vol. 420, Iss. 1, 2001-05 ,pp. : 27-32

Elsevier

Access to resources Recommend Favorite

Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinson’s Disease and L-DOPA Treatment

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 3, 2012-05 ,pp. : 251-263

Bentham Science Publishers

Access to resources Recommend Favorite

Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor

By Bonifacio M.J.   Vieira-Coelho M.A.   Soares-da-Silva P.  

European Journal of Pharmacology, Vol. 460, Iss. 2, 2003-01 ,pp. : 163-170

Elsevier

Access to resources Recommend Favorite

Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-DOPA and dopamine in rats

By Napolitano A.   Zurcher G.   Da Prada M.  

European Journal of Pharmacology, Vol. 273, Iss. 3, 1995-02 ,pp. : 215-221

Elsevier

Access to resources Recommend Favorite